Baillie Gifford Health Innovation B Acc
ISIN: GB00BMVLY038 | MEX: BGAAGB | CITI: T2PD
-
Buy 59.17 GBX
-
Sell 59.17 GBX
-
Price Change 1.11070%
Past Performance
- 12th Nov 2019 to 12th Nov 2020-
- 12th Nov 2020 to 12th Nov 2021-
- 12th Nov 2021 to 12th Nov 2022-25.50%
- 12th Nov 2022 to 12th Nov 2023-31.24%
- 12th Nov 2023 to 12th Nov 202412.47%
Objectives and Approach
The Fund aims to outperform (after deduction of costs) the MSCI ACWI Health Care Index, as stated in sterling, by at least 2.5% per annum over rolling five-year periods.
Key Information
Inception | 15th Dec 2020 |
Historic Yield | 0% |
Sector | IA Healthcare |
Fund Size | £20.507mn |
Fund Type | OEIC |
Classification | Accumulation |
Charges
Total Ongoing Charges
Please note that whilst we endeavour to show all charges associated with specific funds, sometimes this is not possible due to the information not being made available by the fund provider. In such cases transaction or incidental cost information may be missing. |
0.6853% |
Initial Charge | 0% |
AMC | 0.50% |
Our Platform Charge We charge a platform fee of 0.30%. Our charges are shown on our rates and charges sheet |
0.30% |
Cost and Charges Information
This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product
Account Type
Annual charges
These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate
Cost Category | % of Investment | lump sum costs |
---|---|---|
Our annual fee
Our annual feeIncludes our platform fee at 0.30% per annum (excluding Charles Stanley Multi Asset Funds and anycash held). The min fee is £60, the max is £600 per annum, plus SIPP administration fee (if applicable, only charged if < £30,000 held) – see here |
0.30% | |
Dealing charges
Dealing chargesAny one-off commission charges associated with investing. Note that government taxes and levies are not included. This does not include any commission credits you may have available |
N/A | |
Product provider costs
Product provider costsProduct provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs |
0.6853% | |
Total (£)
Total (£)Costs per annum displayed in monetary value |
||
Total (%)
Total (%)Costs per annum displayed as a percentage of investment value |
Cumulative effect of charges on your investment's return
This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges
lump sum invested with an assumed growth rate of | 1 year | years |
---|---|---|
What you might get back at with no charges applied
What you might get back at with no charges appliedThese are the illustrative values of a investment after growth and no costs applied at the end of the defined period |
||
Annual charges
Annual chargesThese are the annual costs based on an initial investment amount of assuming a net zero growth rate |
||
Effect of charges on return (%)
Effect of charges on return (%)These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate |
||
Effect of charges on return (£)
Effect of charges on return (£)These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate |
||
What you might get back at with charges applied
What you might get back at with charges appliedThese are the illustrative values of a investment after growth and costs at the end of the defined period |
This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use
Performance
-
Chart Options
Select TimeframeFromToAdd comparator to chartNone
This fund's IA Sector (IA Healthcare)
Another IA SectorSearch for Fund ComparatorAdd a FTSE Index
Current Comparators -
Cumulative Performance
1 month 3 months 6 months 1 year 3 years 5 years 3.92% 3.05% 2.28% 12.47% -42.39% -
Important Information
Headline performance can mask the true characteristics of a fund. Without fully understanding how a fund is managed, you may inadvertently become exposed to an undesirable level of risk to your capital. Some funds carry a dilution levy which reduces the number of units realised on any initial investment as an initial charge. If this fund carries such a levy it should be detailed in the Key Investor Information Document (KIID), which we must provide and you should read before investing.
The charts and performance data shown are supplied by an external data provider and may contain data that appears to precede the introduction of the clean unit class for this fund. In such cases, historical data has been synthesised at the entire discretion of that external provider as realistically as possible using historical data recorded against the previously available commission-paying version of the fund, adjusting for fees in the process.
Composition
View Fund Allocation by:
Important Documents
The documents listed below are the latest versions made available to our data provider by the fund management group, but may not necessarily reflect the applicable charges that would be levied should you purchase this fund via Charles Stanley Direct. You should treat the charges and other figures shown in the 'Overview' tab as accurate.
The Fact Sheet is supplied on a monthly basis by the management group and provides limited information on the fund. Past performance data and a review of how the fund has performed are commonly featured.
109,018 bytes PDF Document; last updated 31 Aug 2024
44,143 bytes PDF Document; last updated 11 Sep 2024
3,632,504 bytes PDF Document; last updated 30 Jun 2024
3,304,953 bytes PDF Document; last updated 31 Dec 2023
1,286,725 bytes PDF Document; last updated 25 Jul 2024
Management Team
Julia Angeles Marina Record Rose Nguyen
Julia Angeles
has managed this fund for 3 years and 10 months.
Julia joined Baillie Gifford in 2008 and became a partner in 2022. She is a portfolio manager in the Health Innovation Strategy, which she co-founded in 2018, and a member of the International Growth Portfolio Construction Group. Julia previously worked as a management consultant at McKinsey & Company, advising firms in Denmark, Russia and Hungary. She obtained a BSc in 1999, an MSc in 2001 and a PhD in 2005 in Economics from the University of Aarhus, Denmark. She is fluent in Russian and Danish.
Manager Cumulative Performance v Peer Group
All funds managed by Julia
Name of Security | Sole/Co | Managed Since |
---|---|---|
Baillie Gifford Hlth Invtn | Co | Dec 2020 |
Baillie Gifford Ww Hlt Invtn | Co | Oct 2018 |
Marina Record
has managed this fund for 3 years and 10 months.
Marina joined Baillie Gifford in 2008 and is the investment manager of the Health Innovation Strategy. She worked in several global teams before joining Long Term Global Growth, where she developed an interest in healthcare. She joined the Health Innovation Team in January 2018. Marina graduated from the London School of Economics and the Higher School of Economics in Russia with BSc degrees in Banking and Finance and Economics, having studied on these programmes simultaneously.
Manager Cumulative Performance v Peer Group
All funds managed by Marina
Name of Security | Sole/Co | Managed Since |
---|---|---|
Baillie Gifford Hlth Invtn | Co | Dec 2020 |
Baillie Gifford Ww Hlt Invtn | Co | Oct 2018 |
Rose Nguyen
has managed this fund for 3 years and 10 months.
Rose joined Baillie Gifford in 2013 and is the investment manager of the Health Innovation Strategy. She worked on various regional and global strategies before joining the Health Innovation Team as an investment manager at the strategy’s inception in 2018. She believes that the convergence of different technologies will ultimately transform life science. Rose graduated with a BA (Hons) in Economics in 2012 and an MPhil in Finance and Economics in 2013, both from the University of Cambridge.
Manager Cumulative Performance v Peer Group
All funds managed by Rose
Name of Security | Sole/Co | Managed Since |
---|---|---|
Baillie Gifford Hlth Invtn | Co | Dec 2020 |
Baillie Gifford Ww Hlt Invtn | Co | Oct 2018 |